36
Views
3
CrossRef citations to date
0
Altmetric
Miscellaneous

Raising high-density lipoprotein cholesterol with inhibitors of cholesteryl ester transfer protein – a new approach to coronary artery disease

Pages 1365-1368 | Published online: 24 Feb 2005

Bibliography

  • BROUSSEAU ME, SCHAEFER EJ, WOLFE ML iet al.: i Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. iN Engl. J. Med. i (2004) 350:1505–1515.
  • DOGGRELL SA: Statins in the 21st century: end of the simple story? iExpert Opin. Investig. Drugs i (2001) 10:1755–1766.
  • GENEST JJ, McNAMARA JR, SALEM DN, SCHAEFER EJ: Prevalence of risk factors in men with prematurecoronary artery disease. Am. i. i1 iCardiol i (1991) 67:1185–1189.
  • RUBINS HB, ROBINS SJ, COLLINS D iet al.: i Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. iN Engl. I Med. i (1999) 341:410–418.
  • RUBINS HB, DAVENPORT J, BABIKIAN V iet al.: i Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). iCirculation i (2001) 103:2828–2833.
  • GEORGE STEINER AND DIABETESATHEROSCLEROSIS INTERVENTION STUDY INVESTIGATORS: Effect of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. iLancet i (2001) 357:905–910.
  • BARTER PJ, BREWER HB Jr, CHAPMAN MJ iet al: i Cholesteryl ester transfer protein — a novel target for raising HDL and inhibiting atherosclerosis. iArterioscler. Thromb. Vase. Biol. i (2003) 23:160–167.
  • OKAMOTO H, YONEMORI F, WAKITANI K iet al: i A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. iNature i (2000) 46:203–206.
  • DE GROOTH GJ, KUIVENHOVEN JA,STALENHOEF AF iet al.: i Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans — a randomized Phase II dose-response study. iCirculation i (2002) 105:2159–2165.
  • GOTTO AM Jr: High-density lipoproteincholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. iAm. Heart' i (2002) 144(6 Suppl.):S33–S43.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.